Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS

Status: temporarily closed to accrual

This is an open-label, phase 1b study to evaluate the safety, tolerability and preliminary efficacy of IBI188 in combination with Azacitidine in newly diagnosed higher risk MDS patients.

Inclusion Criteria

Newly diagnosed MDS subjects with higher risk.
Age ≥ 18 years old.
Eastern Cooperative Oncology Group score of 0-2.
Adequate organ function.
Subjects should take effective contraceptive measures.
Must sign the Informed Consent Form (ICF), and be able to follow all study procedures. Main

Exclusion Criteria

Subject who has transformed from MDS to AML.
MDS subjects with lower risk.
Subjects who have received chemotherapy.
History of chronic hemolytic anemia
Prior exposure to any anti-CD47 or anti-SIRPα agents.
Subjects participating in another interventional clinical study.

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.